Advances in Symptom Burden, Risk Stratification, and Treatment of Myelofibrosis – Enduring Webcast

Description

Program Description

---

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic cell expansion with bone marrow fibrosis. MF has the worst prognosis of the classic Philadelphia chromosome negative MPNs. Although the most frequent cause of death is hematologic transformation and disease progression, patients with MF are at high risk for other competing causes of morbidity and mortality. The considerable heterogeneity of MF translates into a wide range of outcomes. Given this heterogeneity, risk stratification for individualized management becomes essential in disease treatment.

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals caring for myelofibrosis

Commercial Supporter

---

This activity is supported by an educational grant from CTI BioPharma Corp.